Tag: oral immunotherapy (OIT)

Omalizumab + OIT

Clinical Trial to Evaluate Experimental Treatment in People Allergic to Multiple...

NIH and partners to assess whether Omalizumab can reduce allergic reactions.
FARE Reponse to ICER Report

Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies

FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
AAFA Reponse to ICER Report

Asthma and Allergy Foundation of America Responds to Premature ICER Review...

The AAFA addresses concerns regarding the Final Evidence Report released by the ICER.
Aimmune Reponse to ICER Report

Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final...

Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community.
ICER Final Report

ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not...

The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).
Bacteria

Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food...

First clinical study of a bacterial consortium for treating food allergy will initially be studied in patients with history of peanut allergy.
AAFA Press Release Regarding ICER Review

Asthma and Allergy Foundation of America Elevates Patient Voice in ICER...

Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
FARE-ACAAI-AAN Statement

Joint Statement on Peanut Allergy Therapy Review

Organizations representing patients and allergists urge ICER to adopt a more patient-driven approach to assessing immunotherapies for peanut allergy.
AR101

Phase 3 Trial Data Demonstrates Consistent Safety and Efficacy of AR101...

“Results of the European ARTEMIS trial provide further clinical validation of the safety and efficacy of AR101 for children and adolescents with peanut allergy.”
AR101

Aimmune Announces US FDA Advisory Committee Meeting Date for AR101 for...

The FDA will review Aimmune's Biologics Licence Application for AR101 on September 13, 2019.

Connect with Us

39,061FansLike
737FollowersFollow
2,704FollowersFollow
5,516FollowersFollow
40SubscribersSubscribe